Primary Biliary Cholangitis Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2022-2032), Analyzes DelveInsight | Key Companies - Calliditas Therapeutics, Cara Therapeutics, Chemomab. CymaBay Therapeutics, Eli Lilly, Escient, Ga

DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Biliary Cholangitis Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Primary Biliary Cholangitis market report covers emerging drugs, treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Primary Biliary Cholangitis: An Overview
According to the American Liver Foundation, primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver, called the intrahepatic bile ducts. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension.

Patients with PBC can be asymptomatic or may present with jaundice, pruritus, and fatigue. Other symptoms may include abdominal pain, skin darkening, and xanthomas or xanthelasmas. Individuals may also complain of dry mouth, eyes, bone, muscle, and joint pain. As the disease progresses, symptoms of cirrhosis can develop, including jaundice, edema, ascites, and varices.

Various research has indicated associated environmental trigger in animal models, which includes urinary tract infection, reproductive hormone replacement, nail polish, cigarette smoking and xenobiotics, and toxic waste sites. The inflammation results from a direct insult to environmental factors and toxins.

Primary Biliary Cholangitis Market Key Facts
• There were approximately 24,500 males and more than 111,000 females affected by PBC in the United States in 2021, and it is estimated that the prevalence will increase and reach up to nearly 33,000 males and 149,000 females by 2032.
• Assessments showed that in EU4 and the UK, nearly 15,000 males and more than 90,500 females, respectively, were affected by PBC in 2021, which is expected to increase during the forecast period (2022-2032).
• Among EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of PBC (around 32,000 cases) in 2021. On the other hand, Spain had the lowest number of diagnosed prevalent cases of PBC, with about 10,000 cases.
• Assessments show that Japan had about 44,000 diagnosed prevalent cases of PBC in 2021.
• Many molecules are in the pipeline to treat primary biliary cholangitis patients across many countries to cater to different therapeutic needs. Some of the major late-stage products are likely to hit the market in the upcoming years include seladelpar (CymaBay Therapeutics), elafibranor (Genfit), setanaxib (Genkyotex SA), saroglitazar Mg (Zydus), and linerixibat (GlaxoSmithKline).

Primary Biliary Cholangitis Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Biliary Cholangitis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Primary Biliary Cholangitis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Discover How Primary Biliary Cholangitis Market will Grow by 2032:
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Biliary Cholangitis Epidemiology
The epidemiology section covers detailed insights into the historical and current Primary Biliary Cholangitis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Primary Biliary Cholangitis Epidemiology Segmented as -
• Total Diagnosed Prevalent Cases of PBC in the 7MM (2019-2032)
• Gender-specific Cases of PBC in the 7MM (2019-2032)
• Age-specific Cases of PBC in the 7MM (2019-2032)

Get Key Insights Into the Evolving Primary Biliary Cholangitis Epidemiology Trends:
https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Biliary Cholangitis Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cholangitis market or expected to be launched during the study period. The analysis covers Primary Biliary Cholangitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Primary Biliary Cholangitis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Primary Biliary Cholangitis Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Primary Biliary Cholangitis. Currently, Genfit is leading the therapeutics market with its Primary Biliary Cholangitis drug candidates in the most advanced stage of clinical development.

The Leading Players in the Primary Biliary Cholangitis Therapeutics Market Include:
• Calliditas Therapeutics AB (Calliditas Therapeutics Suisse SA)
• Cara Therapeutics, Inc.
• Chemomab Ltd.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• CymaBay Therapeutics
• Eli Lilly and Company
• Escient Pharmaceuticals
• Future Medicine
• Gannex Pharma
• Genfit
• Gilead Sciences
• GlaxoSmithKline
• Intercept Pharmaceuticals
• Merck
• Mirum Pharmaceuticals
• MYR Pharma
• Nanjing Chia-tai Tianqing Pharmaceutical
• Ohara Pharmaceutical
• Selecta Biosciences
• Zydus Therapeutics
And Many Others

Primary Biliary Cholangitis Emerging and Marketed Drugs Covered in the Report Include:
• Elafibranor: Genfit
• Saroglitazar Magnesium: Zydus Discovery
• TQA3526: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Seladelpar: CymaBay Therapeutics
And Many More

Learn More About the Emerging Therapies & Key Companies in the Primary Biliary Cholangitis Therapeutics Market:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Biliary Cholangitis Competitive Intelligence Analysis
4. Primary Biliary Cholangitis Market Overview at a Glance
5. Primary Biliary Cholangitis Background and Overview
6. Primary Biliary Cholangitis Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Primary Biliary Cholangitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis Seven Major Market Analysis
14. Attribute Analysis
15. Primary Biliary Cholangitis Market Outlook (7 major markets)
16. Primary Biliary Cholangitis Access and Reimbursement Overview
17. KOL Views on the Primary Biliary Cholangitis Market.
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings:
https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Other Trending Reports by DelveInsight-)
- Acute Respiratory Distress Syndrome (ARDS) Market
https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market

- Biliary Tract Cancers (BTCs) Market
https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

- Complicated Urinary Tract Infections Market
https://www.delveinsight.com/report-store/complicated-urinary-tract-infections-market

- Congenital Adrenal Hyperplasia Market
https://www.delveinsight.com/report-store/congenital-adrenal-hyperplasia-market

- Ulcerative Colitis (UC) Market
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market

- Acute On Chronic Liver Failure (ACLF) Market
https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market

- Endometrial Cancer Market
https://www.delveinsight.com/report-store/endometrial-cancer-market

- Axial Spondyloarthritis Market
https://www.delveinsight.com/report-store/axial-spondyloarthritis-market

- Adult-onset Still Disease Market
https://www.delveinsight.com/report-store/adult-onset-still-disease-market

- Amebiasis Market
https://www.delveinsight.com/report-store/amebiasis-market

- Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

- Antibody-mediated Rejection Market
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market

- Candidemia Market
https://www.delveinsight.com/report-store/candidemia-market

- Cardiovascular Calcification Market
https://www.delveinsight.com/report-store/cardiovascular-calcification-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.